Group items tagged

Blackwells Chemist, a community pharmacy in South East London did not meet all the General Pharmaceutical Council (GPhC) standards. The pharmacy was inspected on Thursday (01 June) and it was found it did not keep all its records up to date and accurate, particularly its responsible pharmacist records. Investigation report stated that the principle of Governance and principle of Services, including medicines management was 'not met at all'. Under the principle Governance, the report stated: "The pharmacy generally manages the risks associated with its services adequately. People using the pharmacy can provide feedback or raise concerns. And staff generally protect people's personal information well. Team members know what to do to help protect the welfare of a vulnerable person. The pharmacy has written procedures, but these are not easily accessible to team members to refer to. And they are not regularly updated. So, they may be less useful to staff, and may not reflect current best practice." In the inspection it was found that the pharmacy does not always store its medicines properly. It cannot show that it stores all its medicines requiring cold storage at the appropriate temperatures.

Drugmaker Viatris said on Sunday (October 1) it had reached agreements to divest some of its businesses for a total of about £2.9 billion. Viatris said its move to divest some of its businesses is part of its long-term strategy to streamline focus on three core therapeutic areas - ophthalmology, gastroenterology and dermatology. The company has received an offer of about $2.17 billion (£1.78 billion) for almost all of its over-the-counter drug business from France-based Cooper Consumer Health. Viatris will retain rights for erectile dysfunction drug Viagra, nasal spray Dymista and select OTC drugs within certain markets. Separately, the drugmaker said it has agreed to sell its women's healthcare business to Spanish pharmaceutical company Insud Pharma, while its active pharmaceutical ingredients business in India will be sold to Iquest Enterprises. Both divestitures would result in about $1.2 billion (£987 million) in proceeds.

The Pharmacists' Defence Association (PDA) has urged its member - employed pharmacists and locum pharmacists to share their view on UK Commission on Pharmacy Professional Leadership report. The four government Chief Pharmacists have published their commission's proposal for how pharmacy leadership may develop in the UK. The association 'strongly' believes that just as it was the members of the profession that established their previous pharmacist professional leadership bodies, so it is for pharmacists to determine if they agree with these proposals and to decide what arrangements they want in future. "As an organisation that has exclusively in its membership the employed and locum pharmacists in the UK, the PDA wants to ensure that it can reflect the views of frontline pharmacists in any future discussions and decisions that could impact upon their careers. Pharmacists are encouraged to read the report, to consider its content and then ensure they respond to the forthcoming communication from the PDA." The commission report says that existing leadership bodies have "relatively low levels of membership" but does not provide details. It has also stated that it has received submissions to its consultation from many pharmacy organisations.

In its response to the Health and Social Care Committee inquiry into 'Digital Transformation in the NHS', the Community Pharmacy IT Group (CP ITG) has highlighted issues concerning the NHS community pharmacy. CP ITG, of which PSNC is a member, has urged that pharmacy teams should have access to up-to-date records information, e.g. from Shared Care Records, GP Connect and Summary Care Records with Additional Information. It has also stated that the Booking and Referral Standards (BaRS) should be extended so that future referrals into and from pharmacy can be communicated seamlessly. In its written response, CP ITG said: "Ensure that BaRS is expanded and aligns with other referral IT standards such as GP Connect referrals. Ensure it is used across community pharmacy, the GP sector, other health care sectors and across the NHS, and by all health IT suppliers, so that messages and referrals can flow smoothly within and across sectors and patients can have a seamless experience and safe care." The group has asked the Health and Social Care Committee to create a framework for the development of pharmacy IT to ensure IT suppliers are better equipped to support pharmacy teams and their delivery of services.

Consumer goods giant Unilever signalled on Monday (January 17) it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" after its £50 billion offer was refused. GSK confirmed on Saturday that it had rejected three approaches from the Dove-soap maker, adding it intended to stick to its own plan to spin off the business as a separate company later this year. "GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement as it unveiled a strategy update in the wake of the weekend's takeover news. Unilever said it was "committed to accelerating the company's growth and repositioning the portfolio into higher growth categories. "As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing," Unilever said.

Pharmanovia, a global pharmaceutical company has announced increased targets to divert 40 per cent of its air shipments to sea in 2023, and 75 per cent by the end of 2028. It has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report. Its industry-leading air-to-sea pilot scheme, which focused on its Spain-to-Australia freight route, cut an estimated 470,000kg in potential CO2 emissions in 2022 - reducing Scope 3 upstream transport emissions by 18 per cent. This initiative demonstrates Pharmanovia's role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical companies measured their entire Scope 3 emissions. The new Sustainability Report reveals that the Scope 2 emissions decreasing by 13 per cent in 2022, due to lower direct electricity demand within the office space. The company's packaging audit seeing a 52 per cent increase in the percentage of products packed with at least one fully recyclable component, up from 12% in 2021 to 64 per cent in 2022 Strong progress in an initiative which saw Pharmanovia set ESG goals all employees across its global offices as part of annual performance awards. Employees achieved a 98 per cent completion rate of the compliance training, including ESG modules

The General Pharmaceutical Council (GPhC) has committed to playing its part in addressing climate change by undertaking work to establish a carbon footprint baseline to improve its environmental performance. In a statement on Monday (July 18) the pharmacy regulator laid out what it called its vision "to have safe and effective pharmacy care at the heart of healthier communities". Stating that climate change creates health risks and exacerbates health inequalities, GPHC said: "We believe we all have a role to play in contributing to addressing climate change." It announced that it has just joined "a newly formed cross-regulatory group" formed to address issues such as "environmental sustainability". "At the GPhC we have brought together colleagues from across the organisation to consider the environmental impact we have as an employer and as a regulator," it declared.

Novartis on Wednesday (February 1) predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4 per cent to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya. Novartis said it was on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its focus on its patented prescription medicines. Analysts have welcomed a programme unveiled in 2022 to trim costs and cut 8,000 jobs and plans to focus on fewer therapy areas and drug technologies. But the market has been underwhelmed by prospects for medium-term growth from new drugs.

The results of the Community Pharmacy IT Group's (CP ITG's) IT arrangements survey revealed that 83 per cent of the respondents support the goal of going paperless. The Pharmaceutical Services Negotiating Committee (PSNC) asked community pharmacy teams to complete the survey between late 2021 and October 2022. The survey was designed to gather information on frontline pharmacy teams' perspectives about community pharmacy IT and their pharmacies' IT arrangements. It was found that more than half of pharmacies experience at least one IT outage per month (lasting at least one hour). Over 40% reported poor mobile phone signal and limited internet connectivity options at their pharmacy. 80% agreed that mobile devices would help working within pharmacy, but most reported no laptop and no tablet device available for use in the pharmacy

Weed Oil For Sale Have you been in search of cannabis oil for sale ? In need of thc oil for sale ? Medical Marijuana Buds is your answer. Cannabis oil is one of the most unusual oil amongst the oil range, simply because of the plant from which it is gotten from. Although cannabis and hemp have been used over the years as a natural growing herb, its awareness as a drug in certain parts of the world have strained the relationship between it's users on one hand and legal authorities on the other hand . Not withstanding, Cannabis essential oil is a very useful oil, and is widely regarded as one of the most effective oils for dealing with certain illnesses. Cannabis essential oil is gotten steam distilling the flowers and upper leaves of cannabis plants using steam. THC Oil For Sale Online and enjoy these Benefits: - Anxiety and Stress - Appetite Booster - Pain Reliever - Cancer Prevention - Heart Health - Skin Protection - Glaucoma - Headaches and Migraines Despite the fact that this list clearly shows that cannabis essential oil can effectively be used to cure most of our common health conditions, it still doesn't cancel the fact that it is a potent chemical substance extracted from a plant with psychotropic substances. As such, great care should be taken on its use with respect to the quantity and conditions under which it is being used. It is adviceable to always consult a professional about mixing essential oils and present medications before adding any new elements into your health regime. Medical cannabis oil for sale We do have medical cannabis oil for sale at our online shop which is cheap and affordable for all our customers. Our Cannabis are of great Quality and our standards are incomparable. Purchase from us and get the best for less. Note: If you are looking to buy Cannabis Oil online, hash oil for sale, Medical Marijuana Buds is the right place for you. Feel free to contact our customer service or live help assistance for wha

The World Health Organization says it is tracking a few dozen cases of two new sub-variants of the highly transmissible Omicron strain of the coronavirus to assess whether they are more infectious or dangerous. It has added BA.4 and BA.5, sister variants of the original BA.1 Omicron variant, to its list for monitoring. It is already tracking BA.1 and BA.2 - now globally dominant - as well as BA.1.1 and BA.3. The WHO said on Monday (April 11) it had begun tracking them because of their "additional mutations that need to be further studied to understand their impact on immune escape potential". Viruses mutate all the time but only some mutations affect their ability to spread or evade prior immunity from vaccination or infection, or the severity of disease they cause. For instance, BA.2 now represents nearly 94% of all sequenced cases and is more transmissible than its siblings, but the evidence so far suggests it is no more likely to cause severe disease.

The Royal Pharmaceutical Society (RPS) has called for a 'firm commitment' to prosecuting those making profits through the sale of DNP (2,4-Dinitrophenol). It has also urged the social media companies to 'remove content promoting or selling DNP to further reduce harm'. Legislation to regulate DNP will come into effect on 1 October 2023. On Monday (23 January) it was announced that DNP will be included in the 1972 Poisons Act. President of RPS Professor Claire Anderson said: "DNP is unfit for human consumption and its main use is in the manufacture of explosives and pesticides. It is sold by unscrupulous dealers to vulnerable individuals wanting to lose weight but has a dangerous effect on the metabolism and has led to 32 deaths since 2007 in those taking it as a 'diet drug'. "Including DNP in the Poisons Act is a positive move as it will restrict its availability, but what's really needed is an outright ban to reduce the risk to the public. Australia has already classified DNP as a substance of such a danger to health as to warrant prohibition of sale and we'd like the UK to follow suit.

Medical malpractice is a serious issue, and if you are ever a victim of it, you need to know what to do. More often than not, people do not even know that they are victims of medical malpractice until it is too late. This blog post will discuss six important things that you need to know about medical malpractice. Read on to learn more. IT CAN HAPPEN TO ANYONE First and foremost, medical malpractice can happen to anyone. It does not discriminate based on age, gender, or race. If you have been a victim of medical negligence, then you need to take action. However, many people do not even know that they are victims of medical malpractice until it is too late. This is because the symptoms of medical malpractice can often mimic other conditions or diseases. As such, it is important to be aware of the signs and symptoms of medical malpractice so that you can take action as soon as possible. Some of the most common signs and symptoms of medical malpractice include sudden and unexpected death, severe or permanent injuries, disfigurement, as well as loss of limb. If you or a loved one have experienced any of these symptoms, then it is important to seek legal help as soon as possible. An experienced medical malpractice lawyer will be able to help you investigate your case and determine if you have a valid claim. In this case, take the time to explore online sources where you may come across the websites of some of the most reputable lawyers. This is where you will have the chance to learn about medical malpractice and what you can do to take action. Rest assured that with the help of a competent lawyer, you will be able to get the justice and compensation that you deserve.

Boots is planning to invest more than £3.5 million to accelerate its capacity to offer prescribing services in its stores across England. The company is inviting 500 of its pharmacists to apply for a bursary which will cover the cost of pharmacist independent prescriber (PIP) courses starting this September. The value of the bursary is up to £7,000 per pharmacist, and it will enable time off work for those who need it to complete the training. The move by Boots will support its current pharmacists to gain this qualification via courses accredited by the General Pharmaceutical Council (GPhC). From 2026, all qualified pharmacists will be able to prescribe as part of new curricula for pharmacy degrees. Under current GPhC guidelines and with an independent prescribing qualification, pharmacists can prescribe autonomously for any condition within their clinical competence. Marc Donovan, the chief pharmacist at Boots, said the ambition of the company was "to have a pharmacist prescriber available at every store".

Are you looking for ways technology can improve the health sector? Technology has revolutionized every industry imaginable, so it's no surprise that it has also made its mark on the health sector. In this blog post, we will discuss how technology is helping to improve healthcare for everyone. From telemedicine to mobile apps, technology makes it easier than ever for people to get the care they need. Keep reading to learn more. EASILY ACCESSIBLE MEDICAL INFORMATION One of the biggest ways technology improves healthcare is by making medical information more accessible to everyone. In the past, if you had a question about your health, you would have to either make an appointment with a doctor or do some research on your own. However, thanks to the internet, now you can easily find answers to all of your questions with a few clicks of a button. If you are running a medical facility, it is important to ensure that your IT department is up to date on all of the latest advancements in healthcare technology. As highlighted by the team behind Medicus IT, you can hire an IT health expert to manage all aspects of your digital infrastructure so that you can focus on providing quality patient care. This way, you can ensure that your patients are getting the best possible care.

Lloyds Pharmacy's closure of all its 1,300 branches will wake-up the ministers and NHS officials to the reality of community pharmacy sector in England has reached crisis point, expressed Nigel Swift Managing Director of Rowlands pharmacy and Deputy Managing Director of PHOENIX UK. On Friday, The SUN reported that the UK's second largest pharmacy provider - is allegedly in the process of selling its entire estate of 1300 branches. Lloyds Pharmacy will no longer be a High Street presence following its decision to put all its pharmacy branches at the risk of closure. In January it has announced to close its 237 Sainsbury-based pharmacies. Nigel highlighted the fact that community pharmacy is struggling due to insufficient government funding and immense pressures on GPs and A&E departments - an ongoing issue which poses a very real threat to the sector. Commenting on the announcement, he said: "It's not just Lloyds - an independent analysis by Ernst & Young estimated that 75% of community pharmacies will be in financial distress in the coming years. £750 million has been taken out of the English contract due to inflation since it began."

Anglo-Swedish drugmaker AstraZeneca said on Monday (January 9) that it had struck a deal to buy US-based drug developer CinCor Pharma for up to $1.8 billion to increase its stock of heart and kidney drugs. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease. AstraZeneca aims to combine baxdrostat with its own Farxiga, a diabetes drug whose sales ballooned after it was also shown to benefit patients with heart failure and kidney disease. Farxiga, whose sales jumped by almost 50 per cent during the first nine months of 2022 to reach $3.2 billion, belongs to a highly competitive class of drugs that includes rivals such as Boehringer Ingelheim and Eli Lilly's Jardiance. AstraZeneca gets about a third of its revenue from cancer drugs, but its heart, kidney and diabetes medicines are its second most lucrative business by sales, generating roughly $6.9 billion of the drugmaker's total revenue of more than $33 billion in the first three quarters of 2022.

The Competition and Markets Authority (CMA) has revoked its initial enforcement order imposed on Pharmacy2U Limited (Pharmacy2U) concerning the acquisition of Metabolic Healthcare Ltd (Lloyds Direct). In the revocation order issued on February 12, the regulator said its decision was "based on the evidence it has received in its assessment of the Merger to date." The CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on Pharmacy2U, P2U Holdings Limited, G Square Capital II L.P., G Square Healthcare Private Equity LLP (collectively, the Acquirer Group) and Lloyds Direct on 28 November 2023. It announced that it was considering "whether it is or may be the case that a relevant merger situation has been created and whether the creation of that situation has resulted or may be expected to result in a substantial lessening of competition in any market or markets in the United Kingdom (UK)."

Hey there, folks! Ever find yourself caught up in the throes of pain, wondering if there's a better way to handle it? You're not alone. In fact, according to recent stats, a whopping 93% of people worldwide grapple with pain annually. And get this: 1 in 3 folks deal with it every single day. Crazy, right? But here's the kicker: despite pain being such a prevalent issue, many folks aren't tackling it head-on. Yep, you heard that right. There's a whole lot of suffering going on, and not enough proactive pain management happening. So, what's the solution? Well, that's where our Pain Management Webinar swoops in to save the day! Picture this: an hour jam-packed with enlightening insights, carefully curated to arm you and your team with the tools needed to understand, manage, and ease pain in your patients' lives. Diving Deep: What's Inside the Webinar Alright, buckle up because we're about to dive into the juicy details of what this webinar has in store for you. 1. The Evolving Role of Pharmacists First up, we're shedding light on the evolving role of pharmacists in the realm of pain management. Yep, you heard that right. It's not just about doling out pills anymore. Pharmacists are becoming key players in the fight against pain, and we'll show you exactly how. 2. Decoding Pain Assessment Ever struggle to figure out just how much pain your patients are in? We feel you. That's why we're dedicating some time to decode the art of pain assessment. By the time you're done with this segment, you'll be a pro at understanding and quantifying your patients' pain levels. 3. #ListenToPain: A Campaign for Better Conversations And last but certainly not least, we're shining a spotlight on Haleon's #ListenToPain campaign. This bad boy is all about fostering better conversations between you and your patients. Trust us, folks, communication is key when it comes to pain management, and this campaign's got all the tools you need to nail those conversations. Tailored Jus

The General Pharmaceutical Council (GPhC) has initiated the evaluation of its five-year strategy for changing the way it manage concerns about pharmacy professionals. It has urged people to share their experience of fitness to practice. The evaluation will look at how the strategy has improved the experience of people involved in fitness to practice (those who raise concerns, professionals, witnesses etc.); impacted the culture amongst pharmacy professionals and their attitudes to openness and honesty; improved the process and made it fairer and changed perceptions of fitness to practice. The first phase of the evaluation process will take place from July to September 2023. The council said: "We are committed to making our ambitions a reality for the benefit of everyone involved and your contribution will help us to make sure patients and the public continue to be protected while being fair to pharmacy professionals." In June 2021, GPhC published its five-year strategy- Managing concerns about pharmacy professionals: Guided by its 2030 vision and commitment to equality, diversity and inclusion, the strategy outlines a programme for change.